Kilitch Drugs (India) Limited (KILITCH.BO)
INR 331.45
(-3.93%)
INR 331.45
(-3.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.54 Billion INR | 11.17% |
| 2022 | 1.38 Billion INR | 22.93% |
| 2021 | 1.12 Billion INR | 65.8% |
| 2020 | 681.28 Million INR | 38.63% |
| 2019 | 491.44 Million INR | -39.65% |
| 2018 | 814.28 Million INR | 63.14% |
| 2017 | 499.12 Million INR | 83.77% |
| 2016 | 271.6 Million INR | 29.43% |
| 2015 | 209.85 Million INR | 10.29% |
| 2014 | 190.27 Million INR | 27.72% |
| 2013 | 148.98 Million INR | -55.1% |
| 2012 | 331.8 Million INR | -69.27% |
| 2011 | 1.07 Billion INR | -26.2% |
| 2010 | 1.46 Billion INR | 2.55% |
| 2009 | 1.42 Billion INR | 10.58% |
| 2008 | 1.29 Billion INR | 10.1% |
| 2007 | 1.17 Billion INR | 261.84% |
| 2006 | 323.83 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 334.51 Million INR | -25.36% |
| 2023 Q4 | 448.18 Million INR | 40.96% |
| 2023 Q1 | 365.57 Million INR | -18.28% |
| 2023 Q2 | 412.02 Million INR | 12.71% |
| 2023 Q3 | 317.94 Million INR | -22.83% |
| 2023 FY | 1.54 Billion INR | 11.17% |
| 2022 Q2 | 306.97 Million INR | -8.24% |
| 2022 Q4 | 447.36 Million INR | 49.26% |
| 2022 FY | 1.38 Billion INR | 22.93% |
| 2022 Q1 | 334.52 Million INR | -5.32% |
| 2022 Q3 | 299.72 Million INR | -2.36% |
| 2021 Q3 | 344.31 Million INR | 46.08% |
| 2021 Q1 | 196.24 Million INR | 0.45% |
| 2021 FY | 1.12 Billion INR | 65.8% |
| 2021 Q4 | 353.31 Million INR | 2.62% |
| 2021 Q2 | 235.7 Million INR | 20.11% |
| 2020 FY | 681.28 Million INR | 38.63% |
| 2020 Q4 | 195.37 Million INR | -3.89% |
| 2020 Q3 | 203.27 Million INR | 12.48% |
| 2020 Q2 | 180.72 Million INR | 77.32% |
| 2020 Q1 | 101.91 Million INR | 36.84% |
| 2019 FY | 491.44 Million INR | -39.65% |
| 2019 Q1 | 104.31 Million INR | -42.38% |
| 2019 Q2 | 153.35 Million INR | 47.0% |
| 2019 Q3 | 159.29 Million INR | 3.88% |
| 2019 Q4 | 74.47 Million INR | -53.25% |
| 2018 FY | 814.28 Million INR | 63.14% |
| 2018 Q4 | 181.04 Million INR | 115.09% |
| 2018 Q3 | 84.17 Million INR | -68.62% |
| 2018 Q2 | 268.2 Million INR | -4.5% |
| 2018 Q1 | 280.85 Million INR | 0.0% |
| 2017 FY | 499.12 Million INR | 83.77% |
| 2016 FY | 271.6 Million INR | 29.43% |
| 2015 FY | 209.85 Million INR | 10.29% |
| 2014 FY | 190.27 Million INR | 27.72% |
| 2013 FY | 148.98 Million INR | -55.1% |
| 2012 Q4 | 71.87 Million INR | 108.4% |
| 2012 Q3 | 34.48 Million INR | -47.02% |
| 2012 Q2 | 65.09 Million INR | -57.82% |
| 2012 FY | 331.8 Million INR | -69.27% |
| 2012 Q1 | 154.31 Million INR | 0.0% |
| 2011 FY | 1.07 Billion INR | -26.2% |
| 2010 FY | 1.46 Billion INR | 2.55% |
| 2009 FY | 1.42 Billion INR | 10.58% |
| 2008 FY | 1.29 Billion INR | 10.1% |
| 2007 FY | 1.17 Billion INR | 261.84% |
| 2006 FY | 323.83 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.682% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.143% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 85.317% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 40.453% |
| Achyut Healthcare Limited | 61.36 Million INR | -2415.48% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.332% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.781% |
| Alpa Laboratories Limited | 1.08 Billion INR | -41.966% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.474% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 88.084% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.462% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 67.392% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 79.958% |
| Brooks Laboratories Limited | 794.86 Million INR | -94.213% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.032% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.447% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.317% |
| FDC Limited | 19.42 Billion INR | 92.055% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.693% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.239% |
| Granules India Limited | 45.06 Billion INR | 96.574% |
| Gufic Biosciences Limited | 8.06 Billion INR | 80.863% |
| Hester Biosciences Limited | 3.04 Billion INR | 49.311% |
| Indoco Remedies Limited | 17.89 Billion INR | 91.373% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 87.948% |
| Ipca Laboratories Limited | 76.22 Billion INR | 97.975% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 26.032% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -206.164% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -47.958% |
| Laurus Labs Limited | 50.01 Billion INR | 96.914% |
| Lupin Limited | 200.1 Billion INR | 99.229% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.506% |
| Medicamen Biotech Limited | 1.79 Billion INR | 13.906% |
| Medico Remedies Limited | 1.44 Billion INR | -6.522% |
| Megasoft Limited | 373.95 Million INR | -312.813% |
| Piramal Pharma Limited | 81.71 Billion INR | 98.111% |
| RPG Life Sciences Limited | 5.82 Billion INR | 73.478% |
| Sigachi Industries Limited | 3.98 Billion INR | 61.306% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -104.344% |
| Unichem Laboratories Limited | 16.57 Billion INR | 90.686% |
| Wanbury Limited | 5.75 Billion INR | 73.183% |
| Windlas Biotech Limited | 6.3 Billion INR | 75.534% |
| ZIM Laboratories Limited | 3.67 Billion INR | 57.985% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.188% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 86.591% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 63.352% |
| Bal Pharma Limited | 3.39 Billion INR | 54.492% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.189% |
| Venus Remedies Limited | 5.91 Billion INR | 73.899% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 91.497% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 90.833% |
| Shilpa Medicare Limited | 11.51 Billion INR | 86.595% |
| Aarti Drugs Limited | 25.28 Billion INR | 93.895% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 92.715% |
| Suven Life Sciences Limited | 116.92 Million INR | -1220.224% |
| Ind-Swift Limited | 5.02 Billion INR | 69.277% |
| Valiant Laboratories Limited | 1.82 Billion INR | 15.207% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 95.569% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 87.534% |
| Themis Medicare Limited | 3.81 Billion INR | 59.563% |
| Hikal Limited | 17.84 Billion INR | 91.35% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.544% |
| Sequent Scientific Limited | 13.69 Billion INR | 88.73% |
| Novartis India Limited | 3.35 Billion INR | 53.928% |
| Wockhardt Limited | 27.89 Billion INR | 94.465% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.697% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -285.591% |
| Neuland Laboratories Limited | 15.58 Billion INR | 90.095% |
| Morepen Laboratories Limited | 17.01 Billion INR | 90.929% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 58.119% |